BioMarin Pharmaceutical Inc. (0HNC.L)
USD 66.73
(-0.75%)
USD 66.73
(-0.75%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 194.44 Million USD | 173.86% |
| 2022 | 57.54 Million USD | 195.89% |
| 2021 | -60.01 Million USD | 37.66% |
| 2020 | -96.26 Million USD | 23.27% |
| 2019 | -125.45 Million USD | -1.56% |
| 2018 | -123.52 Million USD | -740.3% |
| 2017 | -14.7 Million USD | 98.17% |
| 2016 | -803.42 Million USD | -625.76% |
| 2015 | -110.7 Million USD | -19.17% |
| 2014 | -92.89 Million USD | 40.46% |
| 2013 | -156 Million USD | -41.55% |
| 2012 | -110.21 Million USD | -225.21% |
| 2011 | -33.89 Million USD | -6329.78% |
| 2010 | 544 Thousand USD | -96.69% |
| 2009 | 16.42 Million USD | -58.68% |
| 2008 | 39.75 Million USD | 169.4% |
| 2007 | -57.28 Million USD | -132.19% |
| 2006 | -24.67 Million USD | 61.58% |
| 2005 | -64.21 Million USD | 64.2% |
| 2004 | -179.36 Million USD | -136.62% |
| 2003 | -75.8 Million USD | 3.86% |
| 2002 | -78.84 Million USD | -51.78% |
| 2001 | -51.94 Million USD | -57.42% |
| 2000 | -33 Million USD | -20.01% |
| 1999 | -27.49 Million USD | -113.17% |
| 1998 | -12.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 103.45 Million USD | 26.38% |
| 2024 Q1 | 81.86 Million USD | 475.72% |
| 2024 Q3 | 113.89 Billion USD | 10.09% |
| 2023 Q4 | 14.21 Million USD | -37.72% |
| 2023 FY | 157.59 Million USD | 173.86% |
| 2023 Q2 | 56.77 Million USD | -6.11% |
| 2023 Q3 | 22.83 Million USD | -59.79% |
| 2023 Q1 | 60.46 Million USD | 534.01% |
| 2022 FY | 57.54 Million USD | 195.89% |
| 2022 Q1 | 29.99 Million USD | 145.53% |
| 2022 Q2 | 39.15 Million USD | 30.54% |
| 2022 Q4 | -13.93 Million USD | -602.05% |
| 2022 Q3 | 2.77 Million USD | -92.91% |
| 2021 FY | -60.01 Million USD | 37.66% |
| 2021 Q3 | -53.21 Million USD | -555.95% |
| 2021 Q2 | 11.67 Million USD | -53.47% |
| 2021 Q1 | 25.08 Million USD | 155.95% |
| 2021 Q4 | -65.88 Million USD | -23.79% |
| 2020 Q1 | 104.96 Million USD | 1245.61% |
| 2020 FY | -96.26 Million USD | 23.27% |
| 2020 Q2 | -40.94 Million USD | -139.01% |
| 2020 Q3 | -55.94 Million USD | -36.62% |
| 2020 Q4 | -44.84 Million USD | 19.84% |
| 2019 Q4 | -9.16 Million USD | -328.48% |
| 2019 Q1 | -53.95 Million USD | -41.43% |
| 2019 Q2 | -41.35 Million USD | 23.35% |
| 2019 FY | -125.45 Million USD | -1.56% |
| 2019 Q3 | 4.01 Million USD | 109.7% |
| 2018 Q4 | -38.14 Million USD | -142.35% |
| 2018 Q3 | -15.74 Million USD | 37.69% |
| 2018 Q2 | -25.26 Million USD | 43.07% |
| 2018 Q1 | -44.37 Million USD | -176.44% |
| 2018 FY | -123.52 Million USD | -740.3% |
| 2017 Q4 | 58.04 Million USD | 522.87% |
| 2017 Q2 | -38.81 Million USD | -92.06% |
| 2017 Q3 | -13.72 Million USD | 64.63% |
| 2017 Q1 | -20.2 Million USD | 77.45% |
| 2017 FY | -14.7 Million USD | 98.17% |
| 2016 Q3 | -60.08 Million USD | 89.51% |
| 2016 Q4 | -89.62 Million USD | -49.16% |
| 2016 Q2 | -572.8 Million USD | -607.89% |
| 2016 Q1 | -80.91 Million USD | -179.86% |
| 2016 FY | -803.42 Million USD | -625.76% |
| 2015 Q1 | -65.86 Million USD | -12.09% |
| 2015 Q4 | 101.31 Million USD | 223.75% |
| 2015 FY | -110.7 Million USD | -19.17% |
| 2015 Q3 | -81.87 Million USD | -27.45% |
| 2015 Q2 | -64.24 Million USD | 2.46% |
| 2014 Q2 | -18.88 Million USD | 28.63% |
| 2014 Q4 | -58.75 Million USD | -624.47% |
| 2014 FY | -92.89 Million USD | 40.46% |
| 2014 Q1 | -26.45 Million USD | 49.42% |
| 2014 Q3 | 11.2 Million USD | 159.33% |
| 2013 Q1 | -32.92 Million USD | 29.81% |
| 2013 Q4 | -52.31 Million USD | -3.13% |
| 2013 FY | -156 Million USD | -41.55% |
| 2013 Q3 | -50.72 Million USD | -152.96% |
| 2013 Q2 | -20.05 Million USD | 39.09% |
| 2012 Q1 | -21.86 Million USD | -2.01% |
| 2012 FY | -110.21 Million USD | -225.21% |
| 2012 Q4 | -46.9 Million USD | -347.09% |
| 2012 Q3 | -10.49 Million USD | 66.11% |
| 2012 Q2 | -30.95 Million USD | -41.56% |
| 2011 Q2 | 768 Thousand USD | -66.52% |
| 2011 Q1 | 2.29 Million USD | 168.48% |
| 2011 FY | -33.89 Million USD | -6329.78% |
| 2011 Q4 | -21.43 Million USD | -38.14% |
| 2011 Q3 | -15.51 Million USD | -2120.44% |
| 2010 FY | 544 Thousand USD | -96.69% |
| 2010 Q1 | 2.79 Million USD | -56.28% |
| 2010 Q2 | 3.04 Million USD | 9.07% |
| 2010 Q3 | -1.93 Million USD | -163.72% |
| 2010 Q4 | -3.35 Million USD | -72.77% |
| 2009 FY | 16.42 Million USD | -58.68% |
| 2009 Q4 | 6.38 Million USD | -37.02% |
| 2009 Q1 | -4.4 Million USD | -113.73% |
| 2009 Q2 | 4.31 Million USD | 198.0% |
| 2009 Q3 | 10.13 Million USD | 134.94% |
| 2008 Q2 | 4.53 Million USD | 453.79% |
| 2008 FY | 39.75 Million USD | 169.4% |
| 2008 Q1 | 818 Thousand USD | 108.73% |
| 2008 Q4 | 32.05 Million USD | 1263.5% |
| 2008 Q3 | 2.35 Million USD | -48.1% |
| 2007 Q2 | -13.6 Million USD | 19.11% |
| 2007 Q1 | -16.81 Million USD | -45.42% |
| 2007 Q4 | -9.37 Million USD | 46.46% |
| 2007 FY | -57.28 Million USD | -132.19% |
| 2007 Q3 | -17.5 Million USD | -28.67% |
| 2006 Q4 | -11.56 Million USD | -180.93% |
| 2006 Q2 | -1.33 Million USD | 82.54% |
| 2006 Q1 | -7.65 Million USD | 40.29% |
| 2006 FY | -24.67 Million USD | 61.58% |
| 2006 Q3 | -4.11 Million USD | -207.85% |
| 2005 Q2 | -18.77 Million USD | 23.15% |
| 2005 FY | -64.21 Million USD | 64.2% |
| 2005 Q4 | -12.82 Million USD | 2.64% |
| 2005 Q3 | -13.17 Million USD | 29.83% |
| 2005 Q1 | -24.42 Million USD | 69.3% |
| 2004 FY | -179.36 Million USD | -136.62% |
| 2004 Q2 | -53.84 Million USD | -178.47% |
| 2004 Q3 | -26.62 Million USD | 50.56% |
| 2004 Q4 | -79.56 Million USD | -198.87% |
| 2004 Q1 | -19.33 Million USD | 23.01% |
| 2003 Q1 | -20.54 Million USD | 21.74% |
| 2003 FY | -75.8 Million USD | 3.86% |
| 2003 Q4 | -25.11 Million USD | -21.49% |
| 2003 Q3 | -20.67 Million USD | -118.11% |
| 2003 Q2 | -9.47 Million USD | 53.87% |
| 2002 Q1 | -24.57 Million USD | -8.98% |
| 2002 Q3 | -15.04 Million USD | -15.96% |
| 2002 FY | -78.84 Million USD | -51.78% |
| 2002 Q4 | -26.25 Million USD | -74.47% |
| 2002 Q2 | -12.97 Million USD | 47.2% |
| 2001 Q2 | -10.66 Million USD | -17.77% |
| 2001 Q4 | -22.55 Million USD | -133.12% |
| 2001 Q3 | -9.67 Million USD | 9.33% |
| 2001 Q1 | -9.05 Million USD | 9.64% |
| 2001 FY | -51.94 Million USD | -57.42% |
| 2000 Q2 | -7.18 Million USD | 4.69% |
| 2000 Q1 | -7.54 Million USD | 17.11% |
| 2000 Q3 | -8.24 Million USD | -14.73% |
| 2000 FY | -33 Million USD | -20.01% |
| 2000 Q4 | -10.02 Million USD | -21.55% |
| 1999 Q3 | -7.8 Million USD | -27.87% |
| 1999 Q2 | -6.1 Million USD | 69.95% |
| 1999 Q4 | -9.09 Million USD | -16.65% |
| 1999 FY | -27.49 Million USD | -113.17% |
| 1999 Q1 | -20.3 Million USD | 0.0% |
| 1998 FY | -12.9 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 214.931% |
| Dynavax Technologies Corporation | -37.02 Million USD | 625.119% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 3790.283% |
| Perrigo Company plc | 151.9 Million USD | -28.006% |
| Illumina, Inc. | -1.06 Billion USD | 118.189% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 97.165% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 142.218% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 101.381% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 90.165% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 275.782% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 95.196% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 535.312% |
| Waters Corporation | 817.67 Million USD | 76.22% |
| Biogen Inc. | 1.29 Billion USD | 85.006% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 170.963% |
| Evolus, Inc. | -49.23 Million USD | 494.94% |
| Adicet Bio, Inc. | -152.03 Million USD | 227.89% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 260.04% |
| bluebird bio, Inc. | -244.26 Million USD | 179.603% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 224.992% |
| FibroGen, Inc. | -281.81 Million USD | 168.996% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 85.597% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 531.35% |
| Homology Medicines, Inc. | -48.25 Million USD | 502.945% |
| Geron Corporation | -193.94 Million USD | 200.256% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 168.908% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 364.567% |
| Myriad Genetics, Inc. | -123.7 Million USD | 257.188% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 292.846% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 137.734% |
| Zoetis Inc. | 3.06 Billion USD | 93.664% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 503.405% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 82.117% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 95.486% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 596.618% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 154.969% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 170.448% |
| Verastem, Inc. | -92.08 Million USD | 311.156% |
| Nektar Therapeutics | -137.42 Million USD | 241.489% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 183.874% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 299.72% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 172.6% |
| OPKO Health, Inc. | -157.02 Million USD | 223.831% |
| Exelixis, Inc. | 170.88 Million USD | -13.785% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 22.503% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -81.243% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 448.736% |
| uniQure N.V. | -282.87 Million USD | 168.738% |
| Imunon, Inc. | -21.03 Million USD | 1024.57% |
| Blueprint Medicines Corporation | -486.27 Million USD | 139.986% |
| Insmed Incorporated | -709.62 Million USD | 127.4% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 42.4% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 149.667% |
| TG Therapeutics, Inc. | 20.63 Million USD | -842.379% |
| Incyte Corporation | 620.52 Million USD | 68.665% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 126.768% |